Effectiveness of 1, 2, and 3 doses of human papillomavirus vaccine against high-grade cervical lesions positive for human papillomavirus 16 or 18
ML Johnson Jones, JW Gargano… - American journal of …, 2020 - academic.oup.com
Abstract Before 2016, human papillomavirus (HPV) vaccination was recommended on a 3-
dose schedule. However, many vaccine-eligible US females received fewer than 3 doses …
dose schedule. However, many vaccine-eligible US females received fewer than 3 doses …
Trends in human papillomavirus vaccine types 16 and 18 in cervical precancers, 2008–2014
NM McClung, JW Gargano, NM Bennett… - … Biomarkers & Prevention, 2019 - AACR
Background: The impact of human papillomavirus (HPV) vaccination has been observed in
the United States through declining cervical precancer incidence in young women. To …
the United States through declining cervical precancer incidence in young women. To …
An evaluation of dose-related HPV vaccine effectiveness using central registries in Michigan
JW Gargano, M You, R Potter, G Alverson… - … Biomarkers & Prevention, 2022 - AACR
Background: Human papillomavirus (HPV) vaccine effectiveness (VE) evaluations provide
important information for vaccination programs. We established a linkage between statewide …
important information for vaccination programs. We established a linkage between statewide …
Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States–2008–2012
S Hariri, NM Bennett, LM Niccolai, S Schafer, IU Park… - Vaccine, 2015 - Elsevier
Background Prevention of pre-invasive cervical lesions is an important benefit of HPV
vaccines, but demonstrating impact on these lesions is impeded by changes in cervical …
vaccines, but demonstrating impact on these lesions is impeded by changes in cervical …
Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions
SE Powell, S Hariri, M Steinau, HM Bauer, NM Bennett… - Vaccine, 2012 - Elsevier
BACKGROUND: Vaccination against human papillomavirus (HPV) types 16 and 18 is
recommended for girls aged 11 or 12 years with catch-up vaccination through age 26 in the …
recommended for girls aged 11 or 12 years with catch-up vaccination through age 26 in the …
Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study
MJ Silverberg, WA Leyden, JO Lam… - The Lancet Child & …, 2018 - thelancet.com
Background The population effectiveness of human papillomavirus (HPV) catch-up
vaccination, defined in the USA as first vaccination at ages 13–26 years, has not been …
vaccination, defined in the USA as first vaccination at ages 13–26 years, has not been …
Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study
AM Rodriguez, B Zeybek, M Vaughn, J Westra, S Kaul… - Cancer, 2020 - Wiley Online Library
Background Human papillomavirus (HPV)–related disease remains a significant source of
morbidity and mortality, and this underscores the need to increase HPV vaccination to …
morbidity and mortality, and this underscores the need to increase HPV vaccination to …
Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: evidence of direct and herd effects of vaccination
LE Markowitz, AL Naleway, RM Lewis, B Crane… - Vaccine, 2019 - Elsevier
Background Human papillomavirus (HPV) vaccine has been recommended in the United
States since 2006 for routine vaccination of girls at age 11–12 years and through age 26 …
States since 2006 for routine vaccination of girls at age 11–12 years and through age 26 …
Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses
LE Markowitz, AL Naleway, NP Klein… - The Journal of …, 2020 - academic.oup.com
Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …
Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination
M Kibur, VA Geijerstamm, E Pukkala… - Sexually transmitted …, 2000 - sti.bmj.com
Background: Identification of human papillomavirus type 16 (HPV16) as the major risk factor
for cervical neoplasia, and mass production of DNA free HPV capsids have paved the way to …
for cervical neoplasia, and mass production of DNA free HPV capsids have paved the way to …